Access cutting-edge glioblastoma treatment through this clinical trial at a research site in Rochester. Study-provided care at no cost to qualified participants.
Access glioblastoma specialists in Rochester at no cost
This study follows strict safety protocols and ethical guidelines
All study-related glioblastoma treatment provided free
This phase II trial tests how well retifanlimab with bevacizumab and hypofractionated radiotherapy, compared to bevacizumab and hypofractionated radiotherapy alone, works in treating patients with glioblastoma that has come back after a period of improvement (recurrent). A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Immunotherapy with monoclonal antibodies, such as retifanlimab
Sponsor: Academic and Community Cancer Research United
Check if you qualify for this glioblastoma clinical trial in Rochester, MN
If you're searching for glioblastoma treatment options in Rochester, MN, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Rochester research site is actively enrolling participants for this clinical trial. You'll receive care from experienced glioblastoma specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.